139 related articles for article (PubMed ID: 17464082)
1. Erythropoietin in cancer: presumption of innocence?
Blau CA
Stem Cells; 2007 Aug; 25(8):2094-7. PubMed ID: 17464082
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietic agents in the management of cancer patients. Part 1: Anemia, quality of life, and possible effects on survival.
Smith RE
J Support Oncol; 2003; 1(4):249-56, 258-9; discussion 257-8. PubMed ID: 15334867
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin in cancer-related anemia.
Fenner MH; Ganser A
Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
[TBL] [Abstract][Full Text] [Related]
5. [Concern about the safety of erythropoietin in cancer patients].
van der Lelie J
Ned Tijdschr Geneeskd; 2008 Apr; 152(16):920-2. PubMed ID: 18561786
[TBL] [Abstract][Full Text] [Related]
6. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin-stimulating agents in oncology.
Savona MR; Silver SM
Cancer J; 2008; 14(2):75-84. PubMed ID: 18391611
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin for oncology supportive care.
McKinney M; Arcasoy MO
Exp Cell Res; 2011 May; 317(9):1246-54. PubMed ID: 21396935
[TBL] [Abstract][Full Text] [Related]
11. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
12. [Anaemia and radiation therapy].
Denis F; Lartigau E
Cancer Radiother; 2004 Nov; 8 Suppl 1():S14-23. PubMed ID: 15679242
[TBL] [Abstract][Full Text] [Related]
13. New Zealand cancer patients should have access to erythropoietin treatment.
Carter J; Clay J
N Z Med J; 2006 May; 119(1234):U1989. PubMed ID: 16718300
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
Mannello F; Tonti GA
Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
[TBL] [Abstract][Full Text] [Related]
15. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
Hadland BK; Longmore GD
J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin in cancer: the new face of an old friend.
Megalakaki C
J BUON; 2008; 13(1):7-16. PubMed ID: 18404780
[TBL] [Abstract][Full Text] [Related]
17. The ASH/ASCO clinical guidelines on the use of erythropoietin.
Lichtin A
Best Pract Res Clin Haematol; 2005; 18(3):433-8. PubMed ID: 15792917
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
19. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
20. Controversial effect of epoetin in cancer: grounds for a translational research exercise?
Apolone G
Eur J Cancer; 2004 Jun; 40(9):1289-91. PubMed ID: 15177486
[No Abstract] [Full Text] [Related]
[Next] [New Search]